Two part commentary on Brexit and drug discovery

On 31 January 2020, the United Kingdom (UK) withdrew from the European Union (EU). Alongside a number of repercussions, the most impactful to the drug discovery sector arguably relates to regulatory affairs on account of adjusting from the European Medicines Agency (EMA) to the Medicines and Healthcare products Regulatory Agency (MHRA). DDW’s Megan Thomas evaluates the current impact of Brexit on the UK drug discovery sector in two parts: Part 1 and Part 2

In these articles, you will learn about:

  • The implications of leaving the EMA
  • The UK’s access to Horizon Europe
  • Updates on the Windsor Framework and Northern Ireland
  • International trade deals with Switzerland
  • The free trade agreement with the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP)
  • An overview of where the UK currently stands
  • Initiatives for innovation for UK scientists
  • What’s next for the UK in a post-EU context.

Read Part 1 and Part 2 now.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free